Buzzetti E. Pinzani M. Tsochatzis E.A.

The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD).

Metabolism. 65: 1038-1048

Non-alcoholic fatty liver disease - a global public health perspective.

J Hepatol. 70: 531-544

Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis.

Hepatology. 52: 1836-1846Gan L.T. Van Rooyen D.M. Koina M.E. McCuskey R.S. Teoh N.C. Farrell G.C.

Hepatocyte free cholesterol lipotoxicity results from JNK1-mediated mitochondrial injury and is HMGB1 and TLR4-dependent.

J Hepatol. 61: 1376-1384

Lipotoxicity in NASH.

J Hepatol. 56: 291-293Dallio M. Sangineto M. Romeo M. Villani R. Romano A.D. Loguercio C. et al.

Immunity as cornerstone of non-alcoholic fatty liver disease: the contribution of oxidative stress in the disease progression.

Int J Mol Sci. 22Masarone M. Rosato V. Dallio M. Gravina A.G. Aglitti A. Loguercio C. et al.

Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease.

Oxidative Med Cell Longev. 2018: 9547613Thomas D.D. Corkey B.E. Istfan N.W. Apovian C.M.

Hyperinsulinemia: an early indicator of metabolic dysfunction.

J Endocr Soc. 3: 1727-1747

From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options.

JHEP Rep. 1: 312-328Stefan N. Haring H.U. Cusi K.

Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.

Lancet Diabetes Endocrinol. 7: 313-324Bril F. Lomonaco R. Orsak B. Ortiz-Lopez C. Webb A. Tio F. et al.

Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis.

Hepatology. 59: 2178-2187Heinrich G. Muturi H.T. Rezaei K. Al-Share Q.Y. DeAngelis A.M. Bowman T.A. et al.

Reduced hepatic carcinoembryonic antigen-related cell adhesion molecule 1 level in obesity.

Front Endocrinol (Lausanne). 8: 54

The CEACAM1 expression is decreased in the liver of severely obese patients with or without diabetes.

Diagn Pathol. 6: 40

Hepatic insulin clearance: mechanism and physiology.

Physiology (Bethesda). 34: 198-215Xu E. Dubois M.J. Leung N. Charbonneau A. Turbide C. Avramoglu R.K. et al.

Targeted disruption of carcinoembryonic antigen-related cell adhesion molecule 1 promotes diet-induced hepatic steatosis and insulin resistance.

Endocrinology. 150: 3503-3512DeAngelis A.M. Heinrich G. Dai T. Bowman T.A. Patel P.R. Lee S.J. et al.

Carcinoembryonic antigen-related cell adhesion molecule 1: a link between insulin and lipid metabolism.

Diabetes. 57: 2296-2303Ghadieh H.E. Russo L. Muturi H.T. Ghanem S.S. Manaserh I.H. Noh H.L. et al.

Hyperinsulinemia drives hepatic insulin resistance in male mice with liver-specific Ceacam1 deletion independently of lipolysis.

Metabolism. 93: 33-43Poy M.N. Yang Y. Rezaei K. Fernstrom M.A. Lee A.D. Kido Y. et al.

CEACAM1 regulates insulin clearance in liver.

Nat Genet. 30: 270-276Najjar S.M. Yang Y. Fernstrom M.A. Lee S.J. Deangelis A.M. Rjaily G.A. et al.

Insulin acutely decreases hepatic fatty acid synthase activity.

Cell Metab. 2: 43-53

CEACAM1 loss links inflammation to insulin resistance in obesity and non-alcoholic steatohepatitis (NASH).

Semin Immunopathol. 36: 55-71Najjar S.M. Ledford K.J. Abdallah S.L. Paus A. Russo L. Kaw M.K. et al.

Ceacam1 deletion causes vascular alterations in large vessels.

Am J Physiol Endocrinol Metab. 305: E519-E529Ghosh S. Kaw M. Patel P.R. Ledford K.J. Bowman T.A. McLnerney M.F. et al.

Mice with null mutation of Ceacam I develop nonalcoholic steatohepatitis.

Hepat Med. 2010: 69-78Ghadieh H.E. Abu Helal R. Muturi H.T. Issa D.D. Russo L. Abdallah S.L. et al.

Loss of hepatic carcinoembryonic antigen-related cell adhesion molecule 1 links nonalcoholic steatohepatitis to atherosclerosis.

Int Hepatol Commun. 4: 1591-1609Horst A.K. Najjar S.M. Wagener C. Tiegs G.

CEACAM1 in liver injury, metabolic and immune regulation.

Int J Mol Sci. 19Russo L. Muturi H.T. Ghadieh H.E. Ghanem S.S. Bowman T.A. Noh H.L. et al.

Liver-specific reconstitution of CEACAM1 reverses the metabolic abnormalities caused by its global deletion in male mice.

Diabetologia. 60: 2463-2474Al-Share Q.Y. DeAngelis A.M. Lester S.G. Bowman T.A. Ramakrishnan S.K. Abdallah S.L. et al.

Forced hepatic overexpression of CEACAM1 curtails diet-induced insulin resistance.

Diabetes. 64: 2780-2790Santiago-Rolon A. Purcell D. Rosado K. Toro D.H.

A comparison of Brunt’s Criteria, the Non-Alcoholic Fatty Liver Disease Activity Score (NAS), and a proposed NAS scoring that includes fibrosis in non-alcoholic fatty liver disease staging.

P R Health Sci J. 34: 189-194

Macrophage heterogeneity in liver injury and fibrosis.

J Hepatol. 60: 1090-1096

Signaling crosstalk mechanisms that may fine-tune pathogen-responsive NFkappaB.

Front Immunol. 10: 433Suryavanshi S.V. Kulkarni Y.A.

NF-kappabeta: a potential target in the management of vascular complications of diabetes.

Front Pharmacol. 8: 798Gregor M.F. Hotamisligil G.S.

Inflammatory mechanisms in obesity.

Annu Rev Immunol. 29: 415-445Abdel-Razzak Z. Garlatti M. Aggerbeck M. Barouki R.

Determination of interleukin-4-responsive region in the human cytochrome P450 2E1 gene promoter.

Biochem Pharmacol. 68: 1371-1381Mari M. Caballero F. Colell A. Morales A. Caballeria J. Fernandez A. et al.

Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis.

Cell Metab. 4: 185-198Cai D. Yuan M. Frantz D.F. Melendez P.A. Hansen L. Lee J. et al.

Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB.

Nat Med. 11: 183-190Manicassamy S. Gupta S. Huang Z. Sun Z.

Protein kinase C-theta-mediated signals enhance CD4+ T cell survival by up-regulating Bcl-xL.

J Immunol. 176: 6709-6716Nagarajan R.P. Chen F. Li W. Vig E. Harrington M.A. Nakshatri H. et al.

Repression of transforming-growth-factor-beta-mediated transcription by nuclear factor kappaB.

Biochem J. 348: 591-596Russo L. Muturi H.T. Ghadieh H.E. Wisniewski A.M. Morgan E.E. Quadri S.S. et al.

Liver-specific rescuing of CEACAM1 reverses endothelial and cardiovascular abnormalities in male mice with null deletion of Ceacam1 gene.

Mol Metab. 9: 98-113Mahmoud A.M. Szczurek M.R. Blackburn B.K. Mey J.T. Chen Z. Robinson A.T. et al.

Hyperinsulinemia augments endothelin-1 protein expression and impairs vasodilation of human skeletal muscle arterioles.

Phys Rep. 4van Uden P. Kenneth N.S. Rocha S.

Regulation of hypoxia-inducible factor-1alpha by NF-kappaB.

Biochem J. 412: 477-484Au P.Y. Martin N. Chau H. Moemeni B. Chia M. Liu F.F. et al.

The oncogene PDGF-B provides a key switch from cell death to survival induced by TNF.

Oncogene. 24: 3196-3205Titchenell P.M. Quinn W.J. Lu M. Chu Q. Lu W. Li C. et al.

Direct hepatocyte insulin signaling is required for lipogenesis but is dispensable for the suppression of glucose production.

Cell Metab. 23: 1154-1166Lee S.J. Heinrich G. Fedorova L. Al-Share Q.Y. Ledford K.J. Fernstrom M.A. et al.

Development of nonalcoholic steatohepatitis in insulin-resistant liver-specific S503A carcinoembryonic antigen-related cell adhesion molecule 1 mutant mice.

Gastroenterology. 135: 2084-2095Wan J. Weiss E. Ben Mkaddem S. Mabire M. Choinier P.M. Thibault-Sogorb T. et al.

LC3-associated phagocytosis in myeloid cells, a fireman that restrains inflammation and liver fibrosis, via immunoreceptor inhibitory signaling.

Autophagy. 16: 1526-1528Musso G. Gambino R. Cassader M.

Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis.

Prog Lipid Res. 52: 175-191Carter-Kent C. Zein N.N. Feldstein A.E.

Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment.

Am J Gastroenterol. 103: 1036-1042

Mechanisms of hepatic fibrogenesis.

Gastroenterology. 134: 1655-1669Yokota T. Ma R.C. Park J.Y. Isshiki K. Sotiropoulos K.B. Rauniyar R.K. et al.

Role of protein kinase C on the expression of platelet-derived growth factor and endothelin-1 in the retina of diabetic rats and cultured retinal capillary pericytes.

Diabetes. 52: 838-845Rosso C. Kazankov K. Younes R. Esmaili S. Marietti M. Sacco M. et al.

Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.

J Hepatol. 71: 1012-1021Lester S.G. Russo L. Ghanem S.S. Khuder S.S. DeAngelis A.M. Esakov E.L. et al.

Hepatic CEACAM1 over-expression protects against diet-induced fibrosis and inflammation in white adipose tissue.

Front Endocrinol (Lausanne). 6: 116-122Nakamura K. Kageyama S. Kaldas F.M. Hirao H. Ito T. Kadono K. et al.

Hepatic CEACAM1 expression indicates donor liver quality and prevents early transplantation injury.

J Clin Invest. 130: 2689-2704Musso G. Cassader M. Paschetta E. Gambino R.

Pioglitazone for advanced fibrosis in nonalcoholic steatohepatitis: new evidence, new challenges.

Hepatology. 65: 1058-1061Ghadieh H.E. Muturi H.T. Russo L. Marino C.C. Ghanem S.S. Khuder S.S. et al.

Exenatide induces carcinoembryonic antigen-related cell adhesion molecule 1 expression to prevent hepatic steatosis.

Int Hepatol Commun. 2: 35-47